LUMO Lumos Therapeutics: Rasio rega marang prakiraan pendapatan

Lumos Pharma, Inc. - logo grafis emiten LUMO

The forward revenue multiple reflects the dynamics of a biotech company whose operations rely on patents within the US rare metabolic pathology niches. 16.90 captures the value of this parameter. The competitive advantage of Lumos Pharma, Inc. (LUMO) lies in replacing pediatric injections with convenient tablets for endocrine disorders. Stable management is currently focusing on the commercialization of its primary R&D candidate, maintaining shareholder confidence following successful trials.

Lumos Pharma - Rasio kapitalisasi marang dodolan sing dikarepake LUMO (periode 04.07.2022 - 21.12.2024)

Ringkesan rincian data analitis lumos-pharma.com (LUMO)

Ringkesan analitik perusahaan:Lumos Pharma Inc (LUMO)
Produk asli Lumos Pharma, Inc.

Forward P/S determines investment attractiveness by comparing current market capitalization with projected revenue to identify overpayment for future success. By analyzing this forward price-to-sales chart, an investor assesses the sustainability of the premium on the assets of Lumos Pharma, Inc. (LUMO), whose market value is supported by exceptional patent barriers and orphan drug status, which minimize competitive risks during therapy development.

Pesaing Lumos Pharma, Inc.

Rasio rega marang prakiraan pendapatan ascendispharma.com ASND|Madrigal Corp (MDGL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CORT - Rasio rega marang prakiraan pendapatan|RYTM: Rasio rega marang prakiraan pendapatan|AKRO: Multiplikator Forward P/S|MTSR - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan MoonLake Corp|Crinetics Corp (CRNX) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan newamsterdampharma.com (NAMS)|Multiplikator forward rega marang pendapatan soleno.life SLNO|Multiplikator Forward P/S FOLD (amicusrx.com)|Rasio kapitalisasi marang dodolan sing dikarepake 89bio (ETNB)|Agios - Multiplikator Forward P/S|Structure Corp - Rasio rega marang pendapatan sing dikarepake|mimedx.com (MDXG) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan RZLT (rezolutebio.com)|LXRX (Lexicon Pharmaceuticals Inc) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan MBX|Rasio rega marang prakiraan pendapatan Altimmune Pharma (ALT)|Rasio rega marang prakiraan pendapatan AARD (Aardvark Therapeutics Corp)|Multiplikator Forward P/S SGMT (Sagimet Biosciences, Inc.)|BioAge (BIOA) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|BMEA: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan QNCX (Quince Therapeutics Inc)|GUTS (Fractyl) - Multiplikator forward rega marang pendapatan|vTv Therapeutics, Inc. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Agape ATP Corp.|Multiplikator forward rega marang pendapatan Pluri (PLUR)|Multiplikator Forward P/S SYBX|Rasio kapitalisasi marang dodolan sing dikarepake Lipocine Inc|Rasio rega marang prakiraan pendapatan Matinas BioPharma Holdings MTNB|Rasio kapitalisasi marang dodolan sing dikarepake Spruce Biosciences (SPRB)|GLTO: Multiplikator forward rega marang pendapatan|Rega mangsa ngarep marang pendapatan CTCX|ONVO: Multiplikator Forward P/S|RDUS (Radius Recycling) - Rasio rega marang prakiraan pendapatan